# EgyHealth 360 — Deep Planning Audit Pass 2 Summary

> **V3 applicability:** Historical EH-004 planning audit. Its product/UI/month-plan and old milestone references describe that audit stage. Product V3 policy supersedes current direction; M0–M2 are COMPLETE, V3-I1/EACCE/UI NOT STARTED and design FROZEN. Clinical-source/research evidence remains bounded and retained; this is not a new audit or implementation-readiness declaration. See [approved policy/lineage](PRODUCT_V3_DECISIONS.md).

## Audit objective
Prevent the graduation project from entering implementation with only breadth-level planning. This pass deepens the academic evidence, clinical-rule sourcing, experimental methodology, engineering traceability, UX behavior, thesis structure, and six-month execution plan.

## Deliverables completed

### 1. Academic literature / related work
- `docs/research/LITERATURE_REVIEW.md`
- `docs/research/RELATED_WORK_MATRIX.md`

Result:
The project no longer relies on a vague claim that missing EHR data is a problem. The literature basis and related-work boundaries are documented, including evidence that some care gaps are uncertain because available records are insufficient.

### 2. Competitor evidence
- `docs/research/COMPETITOR_EVIDENCE_MATRIX.md`

Result:
The project explicitly acknowledges that Epic, Oracle Health, athenahealth, DIME, and SehaFile already provide important care-gap/follow-up/longitudinal-data capabilities. The USP is not generic care-gap detection, reminders, FHIR, or a patient timeline.

### 3. Clinical-rule source audit
- `docs/research/CLINICAL_RULE_SOURCE_AUDIT.md`
- `docs/research/CLINICAL_RULE_CATALOG_V1.md`

Frozen V1 research rule:
`CR-HTN-FU-001 — Controlled uncomplicated hypertension follow-up`.

Primary source:
WHO 2021 hypertension guideline, Recommendations 6 and 7.

Key operationalization:
- uncomplicated adult synthetic HTN cohort;
- control evidence below 140/90 mmHg;
- 3–6 month follow-up window;
- 6-month overdue boundary;
- no invented automatic medical exemptions.

Source-verified medication-change monthly follow-up is deferred because it would expand the medication-treatment domain.

### 4. Formal research protocol
- `docs/research/EXPERIMENT_PROTOCOL_V1.md`
- `docs/research/METRICS_SPEC_V1.md`

Frozen design includes:
- Synthea v4.0.0 / commit 0185c09 / FHIR R4;
- one care-action case per patient;
- complete-record ground truth before corruption;
- B0 naive comparator;
- B1 normalized coverage-blind comparator;
- P1 full EACCE;
- four corruption families;
- 0–50% missingness;
- five fixed corruption seeds;
- observable and silent missingness modes;
- development benchmark and locked final holdout;
- paired bootstrap CIs and confirmatory McNemar testing;
- false-gap rate as primary outcome;
- recall + decision coverage required next to abstention-based improvement.

### 5. Formal diagrams
- `docs/diagrams/SYSTEM_DIAGRAMS_V1.md`

Includes:
- context diagram;
- component architecture;
- domain boundaries;
- product evaluation/re-evaluation/review sequences;
- CarePlan/CareAction/Assessment state models;
- closure-decision flow;
- logical ERD;
- research pipeline;
- ground-truth trust boundary;
- authorization trust boundary;
- local deployment;
- use-case overview.

### 6. Requirements traceability
- `docs/REQUIREMENTS.md` upgraded to V2 with numbered functional/acceptance/error/NFR requirements.
- `docs/TRACEABILITY_MATRIX_V1.md`

Result:
Core problems now trace to functional requirements, business rules, screens/APIs, acceptance criteria, and planned tests.

### 7. Critical UX validation
- `docs/UX_VALIDATION_V2.md`

Covers:
- nine critical screens;
- loading/empty/error/stale/permission states;
- patient vs clinician terminology;
- responsive rules;
- RTL validation;
- accessibility;
- no-fake-metrics rule;
- TRUE_GAP vs UNCERTAIN distinction.

### 8. Thesis/report plan
- `docs/THESIS_STRUCTURE_V1.md`

Result:
The final report is planned now and should be updated by milestone, not written from scratch at the end.

### 9. Six-month execution plan + risk register
- `docs/PROJECT_PLAN_6_MONTHS.md`

Result:
Six months are divided into deep foundation/bootstrap, identity/security, clinical planning/EACCE, product/research pipeline, Evaluation Lab, and final holdout/hardening/report/demo with explicit buffers and risk mitigations.

### 10. Execution policy
- `docs/EXECUTION_POLICY.md`

Result:
The project is explicitly AI-agent-executed, uses desk research/public/authoritative/synthetic data, and does not depend on team members manually coding or visiting doctors/collecting real patient data unless the supervisor explicitly introduces such a requirement.

## Important corrections made during Pass 2
1. Planning breadth was not treated as final planning depth.
2. Generic care-gap detection was rejected as a novelty claim.
3. A medication-change follow-up rule was not pulled into V1 merely because it exists in WHO guidance.
4. Primary research was narrowed to the actual false-gap-under-incomplete-evidence question.
5. A stronger coverage-blind comparator B1 was added to avoid a strawman baseline.
6. Multiclass macro-F1 was removed as a primary thesis metric rather than artificially balancing product states.
7. Silent missingness was promoted to a mandatory robustness/limitation experiment.
8. Closure decision ordering was frozen so COMPLETED/SCHEDULED can resolve before NOT_DUE and TRUE_GAP remains reachable only after overdue + sufficient coverage.

## P0 blockers after audit
None identified for EH-003 bootstrap.

EH-003 remains a tooling/bootstrap task and does not depend on unresolved clinical implementation details.

## P1 items that must be resolved before their dependent milestone

### Before M2/M3 care-action/EACCE implementation
- freeze the exact product scheduling-validity contract for `SCHEDULED`;
- freeze executable rule representation/DSL/typed contract;
- verify exact care-action occurrence/idempotency key behavior.

### Before M5 final research pipeline
- freeze complete versioned FHIR concept/code sets for HTN eligibility exclusions (CVD/DM/CKD/pregnancy), encounter matching, and BP normalization against Synthea v4.0.0;
- validate generated FHIR fixtures and adapter behavior;
- freeze final Synthea config/artifact hash.

Known Synthea v4.0.0 concepts already verified for implementation preparation include:
- Essential hypertension SNOMED-CT `59621000`;
- Follow-up encounter SNOMED-CT `390906007`;
- BP panel LOINC `85354-9`;
- systolic LOINC `8480-6`;
- diastolic LOINC `8462-4`.

These P1 items are intentionally milestone-gated; they are not reasons to block monorepo/bootstrap implementation.

## Exit-gate judgment
EH-004 Deep Planning Audit Pass 2 satisfies its pre-coding objective:
- evidence/related work documented;
- competitor differentiation documented;
- first clinical rule source-traceable;
- research protocol implementation-ready at architecture/method level;
- diagrams and traceability present;
- critical UX behavior specified;
- thesis/report plan established;
- six-month plan/risk controls established;
- no unresolved P0 planning ambiguity identified for bootstrap.

Recommended next action after merge:
1. mark EH-004 complete;
2. update project state to `EH-003 READY FOR CODING`;
3. resume only EH-003 Bootstrap V2;
4. review EH-003 PR before allowing M1 work.
